CRH Plc/ IE0001827041 /
2024-05-23 10:10:00 PM | Chg. +0.16 | Volume | Bid11:02:00 PM | Ask11:02:00 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
80.41USD | +0.20% | 3.06 mill. Turnover: 191.32 mill. |
79.70Bid Size: 100 | 84.00Ask Size: 200 | 58.21 bill.USD | 1.65% | 18.44 |
GlobeNewswire
05-06
ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2024
GlobeNewswire
03-28
Predictive Oncology Reports Year End 2023 Financial Results and Provides Business Update
GlobeNewswire
03-14
HEALWELL AI Announces New Commercial Agreements with WELL HEALTH USA and Circle Medical, Bringing AI...
GlobeNewswire
02-26
ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2023
GlobeNewswire
02-12
Martin Marietta Announces Acquisition of Aggregates Operations From Affiliates of Blue Water Industr...
GlobeNewswire
01-30
Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia
GlobeNewswire
2023-12-18
Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate
GlobeNewswire
2023-12-11
Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (lu...
GlobeNewswire
2023-12-11
Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib ...
GlobeNewswire
2023-11-21
Martin Marietta to Divest South Texas Cement and Related Concrete Operations to CRH plc
GlobeNewswire
2023-11-14
Predictive Oncology Reports Third Quarter 2023 Financial Results and Provides Business Update
GlobeNewswire
2023-10-30
Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug ...
GlobeNewswire
2023-10-27
ORYZON Reports Financial Results and Corporate Updates for Quarter Ended September 30, 2023
GlobeNewswire
2023-10-23
Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th
GlobeNewswire
2023-10-16
Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th Int...